Nicholas Mitsiades

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. Fiskus W, Mitsiades N. B-Raf Inhibition in the Clinic: Present and Future. Annu Rev Med. 2016;67:29-43 pubmed publisher
    ..Combinatorial approaches targeting the Raf pathway hold promise for even more substantial clinical benefits in the future. ..
  2. Geng C, Rajapakshe K, Shah S, Shou J, Eedunuri V, Foley C, et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014;74:5631-43 pubmed publisher
    ..Overall, our studies highlight the AR axis as the key transcriptional output of SPOP in prostate adenocarcinoma and provide an explanation for the prostate-specific tumor suppressor role of wt-SPOP. ..
  3. Kaochar S, Mitsiades N. A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab. 2018;29:366-368 pubmed publisher
    ..Recently, Sharifi and colleagues reported an additional mechanism that can enhance local androgenic exposure: downregulation of an androgen-inactivating enzyme. ..
  4. Foley C, Mitsiades N. Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer. 2016;7:84-103 pubmed publisher
  5. Mitsiades N, Chew S, He B, Riechardt A, Karadedou T, Kotoula V, et al. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci. 2011;52:7248-55 pubmed publisher
    ..The impact of B-Raf and MEK inhibitors on G?-mutant UMs remains unknown...
  6. Mitsiades N, Sung C, Schultz N, Danila D, He B, Eedunuri V, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72:6142-52 pubmed publisher